LONDON (dpa-AFX) - Hikma Pharmaceuticals (HIK, HIK.L) has agreed with Xellia
Pharmaceuticals to acquire parts of its US finished dosage form business and
assets, including a commercial portfolio and pipeline of differentiated
products, a manufacturing facility in Cleveland, Ohio, sales and marketing
capabilities, and an R&D center in Zagreb, Croatia. Hikma will pay a cash
consideration of $135 million, and an additional contingent consideration of up
to $50 million. The acquisition will add eight approved and marketed injectable
products to Hikma's US portfolio and 11 pipeline products.

Hikma Pharmaceuticals expects the acquisition to be neutral to Group core
earnings in the first 12 months following closing and accretive thereafter, with
meaningful longer-term benefits.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX